Combination therapy with SGLT2 inhibitors and ACEIs/ARBs in T2DM is known to be more effective and well-tolerated than ACEI/ARB alone and yielded better treatment outcomes in terms of control of blood pressure, improvement of renal outcomes, improvement of long-term renal function, and a decrease in blood glucose and body weight Tian B. In non-diabetic patients with albuminuric CKD, treatment with the combination of ACEIs/ARBs and SGLT2 inhibitor significantly increased kidney failure-free survival (Vart et al., 2022). Here, SLC5A2 is linked to type 2 diabetes mellitus.